Warning letter
Bell-More Laboratories, Inc.: warning letter of Jan 5, 2007
FDA warning letter UCM076229 · Baltimore District Office
Key facts
| Reference number | UCM076229 |
|---|---|
| Company | Bell-More Laboratories, Inc. |
| Subject | CGMP Deviations |
| Issue date | Jan 5, 2007 |
| Posted date | Jan 5, 2007 |
| Issuing office | Baltimore District Office |
| Product type | Unknown |
| CFR sections cited | 211.58, 211.42(a), 211.42(c), 211.67(a), 211.100(a), 211.113(b), 211.160(a), 211.67(c) |
| Country | 3 |
| Inspection city | Hampstead |
| Inspection ZIP | 21074-2213 |
| Inspection start date | Aug 7, 2006 |
| Letter on fda.gov | web.archive.org |
At a glance
- 1–9 CFR sections cited
- OAI Linked inspection classification
- Yes Form FDA 483 issued
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA warning letters
FDA warning letters notify a firm of significant regulatory violations found during an inspection or review and request prompt corrective action.
Source: U.S. Food and Drug Administration (FDA), Warning Letters · Source date: